Literature DB >> 26870299

Predicting the failure of retrograde ureteral stent insertion for managing malignant ureteral obstruction in outpatients.

Jin-You Wang1, Hai-Liang Zhang1, Yao Zhu1, Xiao-Jian Qin1, B O Dai1, Ding-Wei Ye1.   

Abstract

Malignant ureteral obstruction (MUO) is an unpropitious sign that is commonly observed in patients with advanced incurable cancer. The present study aimed to evaluate predictive factors for the failure of retrograde ureteral stent insertion in the management of MUO in outpatients. A total of 164 patients with MUO were retrospectively assessed in this study. Clinical factors, including age, gender, type of malignancy, level of obstruction, cause of obstruction, pre-operative creatinine level, degree of hydronephrosis, condition of the contralateral ureter, prior radiotherapy, Eastern Cooperative Oncology Group performance status (ECOG PS), bladder wall invasion and technical failure, were recorded for each case. Univariate and multivariate logistic regression analyses were used to investigate the risk factors for predicting the failure of retrograde ureteral stent insertion. In total, 38 out of 164 patients experienced bilateral obstruction, therefore, a total of 202 ureteral units were available for data analysis. The rate of insertion failure in MUO was 34.65%. Multivariate analyses identified ECOG PS, degree of hydronephrosis and bladder wall invasion as independent predictors for insertion failure. Overall, the present study found that rate of retrograde ureteral stent insertion failure is high in outpatients with MUO, and that ECOG PS, degree of hydronephrosis and bladder invasion are potential independent predictors of insertion failure.

Entities:  

Keywords:  malignant ureteral obstruction; predictive factor; retrograde ureteral stenting

Year:  2015        PMID: 26870299      PMCID: PMC4727034          DOI: 10.3892/ol.2015.3961

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  17 in total

1.  Outcomes of metallic stents for malignant ureteral obstruction.

Authors:  Zachariah G Goldsmith; Agnes J Wang; Lionel L Bañez; Michael E Lipkin; Michael N Ferrandino; Glenn M Preminger; Brant A Inman
Journal:  J Urol       Date:  2012-07-20       Impact factor: 7.450

2.  The management of ureteric obstruction secondary to malignant pelvic disease.

Authors:  S V Chitale; S Scott-Barrett; E T S Ho; N A Burgess
Journal:  Clin Radiol       Date:  2002-12       Impact factor: 2.350

3.  Multicenter experience with metallic ureteral stents for malignant and chronic benign ureteral obstruction.

Authors:  Achal P Modi; Chad R Ritch; David Arend; Rhonda M Walsh; Maria Ordonez; Jaime Landman; Mantu Gupta; Bodo E Knudsen
Journal:  J Endourol       Date:  2010-07       Impact factor: 2.942

4.  The management of malignant ureteral obstruction treated with ureteral stents.

Authors:  Anjali M Ganatra; Kevin R Loughlin
Journal:  J Urol       Date:  2005-12       Impact factor: 7.450

5.  Stent-change therapy in advanced malignancies with ureteral obstruction.

Authors:  Bradley H Rosenberg; Fernando J Bianco; David P Wood; Jeffrey A Triest
Journal:  J Endourol       Date:  2005 Jan-Feb       Impact factor: 2.942

6.  Predicting the success of retrograde stenting for managing ureteral obstruction.

Authors:  O Yossepowitch; D A Lifshitz; Y Dekel; M Gross; D M Keidar; M Neuman; P M Livne; J Baniel
Journal:  J Urol       Date:  2001-11       Impact factor: 7.450

7.  15-year experience with the management of extrinsic ureteral obstruction with indwelling ureteral stents.

Authors:  Steve Y Chung; Robert J Stein; Douglas Landsittel; Benjamin J Davies; David C Cuellar; Ronald L Hrebinko; Tatum Tarin; Timothy D Averch
Journal:  J Urol       Date:  2004-08       Impact factor: 7.450

Review 8.  Ureteral metal stents: 10-year experience with malignant ureteral obstruction treatment.

Authors:  Evangelos N Liatsikos; Dimitrios Karnabatidis; Konstantinos Katsanos; Panagiotis Kallidonis; Paraskevi Katsakiori; George C Kagadis; Nikolaos Christeas; Zafiria Papathanassiou; Petros Perimenis; Dimitrios Siablis
Journal:  J Urol       Date:  2009-12       Impact factor: 7.450

9.  Success of ureteral stents for intrinsic ureteral obstruction.

Authors:  David L Wenzler; Simon P Kim; Henry M Rosevear; Gary J Faerber; William W Roberts; J Stuart Wolf
Journal:  J Endourol       Date:  2008-02       Impact factor: 2.942

10.  Malignant ureteral obstruction: outcomes after intervention. Have things changed?

Authors:  Lih-Ming Wong; Laurence K Cleeve; Alvin D Milner; Alexander G Pitman
Journal:  J Urol       Date:  2007-05-17       Impact factor: 7.450

View more
  9 in total

1.  Percutaneous antegrade ureteral stent placement: single center experience.

Authors:  Güven Kahriman; Nevzat Özcan; Aytaç Doğan; Hakan İmamoğlu; Abdullah Demirtaş
Journal:  Diagn Interv Radiol       Date:  2019-03       Impact factor: 2.630

2.  Can preoperative ureteral stents reduce the incidence of ureteral stricture after radiotherapy in patients with cervical cancer?

Authors:  Liang Liu; Chunhong Yu; Fuzhen Sun; Tao Yang; Dong Wei; Gang Wang; Shoubin Li; Junjiang Liu
Journal:  BMC Urol       Date:  2022-07-18       Impact factor: 2.090

3.  Antegrade double-J stent placement for the treatment of malignant obstructive uropathy: A retrospective cohort study.

Authors:  Ghassen Tlili; Houssem Ammar; Sonia Dziri; Khaled Ben Ahmed; Waad Farhat; Sofiene Arem; Emir Acacha; Rahul Gupta; Arib Rguez; Mehdi Jaidane
Journal:  Ann Med Surg (Lond)       Date:  2021-08-16

4.  Use of metallic and polymeric ureteral stents in malignant ureteral obstruction.

Authors:  Mari Ohtaka; Takashi Kawahara; Yutaro Hayashi; Ryosuke Kobayashi; Sohgo Tsutsumi; Kimito Ousaka; Akitoshi Takizawa; Takeshi Kishida; Masahiro Yao; Hiroji Uemura
Journal:  BJUI Compass       Date:  2020-10-15

5.  Fluoroscopy-guided trans-urethral exchange of double-J ureteral stents.

Authors:  JungWon Kwak; Sung Bum Cho
Journal:  BMC Urol       Date:  2022-06-15       Impact factor: 2.090

6.  Urological Management of Extramural Malignant Ureteric Obstruction: A Survey of Irish Urologists.

Authors:  Eabhann M O'Connor; Gregory J Nason; Eamon A Kiely
Journal:  Curr Urol       Date:  2017-11-30

7.  Gastrointestinal cancer and bilateral hydronephrosis resulted in a high risk of ureteral stent failure.

Authors:  Mari Ohtaka; Takashi Kawahara; Daiji Takamoto; Taku Mochizuki; Yusuke Hattori; Jun-Ichi Teranishi; Kazuhide Makiyama; Yasuhide Miyoshi; Yasushi Yumura; Masahiro Yao; Hiroji Uemura
Journal:  BMC Urol       Date:  2018-05-08       Impact factor: 2.264

8.  Retrograde pyelography predicts retrograde ureteral stenting failure and reduces unnecessary stenting trials in patients with advanced non-urological malignant ureteral obstruction.

Authors:  Sung Han Kim; Boram Park; Jungnam Joo; Jae Young Joung; Ho Kyung Seo; Jinsoo Chung; Kang Hyun Lee
Journal:  PLoS One       Date:  2017-09-20       Impact factor: 3.240

9.  Antegrade double-J stenting as an alternative to the retrograde approach: experience of the first 150 cases at a single center in Brazil.

Authors:  Renata Motta Grubert; Carlos Egydio Ferri do Carmo; Reinaldo Santos Morais Neto; Tiago Kojun Tibana; Rômulo Florêncio Tristão Santos; Edson Marchiori; Thiago Franchi Nunes
Journal:  Radiol Bras       Date:  2021 Nov-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.